CEL-SCI Co. $CVM Shares Bought by MAI Capital Management

Key Points

• MAI Capital Management increased its stake in CEL-SCI Co. by 229.9%, acquiring an additional 366,880 shares to own a total of 526,480 shares valued at $121,000.
• CEO Geert R. Kersten purchased 29,197 shares of CEL-SCI stock at an average price of $6.85, which represents a significant 66.91% increase in his position within the company.
• Wall Street analysts have issued a "sell" rating on CEL-SCI's stock, which recently opened at $10.49 and has a market capitalization of $72.19 million.

MAI Capital Management increased its stake in CEL-SCI Co. (NYSE:CVM - Free Report) by 229.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 526,480 shares of the company's stock after acquiring an additional 366,880 shares during the period. MAI Capital Management owned approximately 0.63% of CEL-SCI worth $121,000 as of its most recent SEC filing.

Analysts Set New Price Targets

Separately, Wall Street Zen started coverage on CEL-SCI in a research report on Friday, May 16th. They set a "sell" rating for the company.

Insider Transactions at CEL-SCI

In other news, CEO Geert R. Kersten purchased 29,197 shares of the stock in a transaction on Friday, July 25th. The stock was purchased at an average price of $6.85 per share, with a total value of $199,999.45. Following the completion of the transaction, the chief executive officer owned 72,835 shares in the company, valued at approximately $498,919.75. The trade was a 66.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 14.06% of the company's stock.

CEL-SCI Trading Up 4.3%

CVM stock traded up $0.42 during trading on Friday, reaching $10.25. 95,083 shares of the stock traded hands, compared to its average volume of 366,905. The business's 50 day moving average price is $7.93 and its 200-day moving average price is $6.67. CEL-SCI Co. has a 52-week low of $1.98 and a 52-week high of $39.30. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09. The firm has a market capitalization of $70.54 million, a PE ratio of -21.35 and a beta of 0.54.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.